Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis
Conclusion: There were no significant differences in clinical outcomes, including acute exacerbation and all-cause mortality among various ICS/LAMA/LABA combinations in patients with moderate to very severe COPD.Respiration
Source: Respiration - Category: Respiratory Medicine Source Type: research
More News: Advair | Advair Diskus | Cardiology | Cardiovascular | Chronic Obstructive Pulmonary | Clinical Trials | Corticosteroid Therapy | Databases & Libraries | Flonase | Flovent | Heart | Pneumonia | Respiratory Medicine | Spiriva | Statistics | Study | Tiotropium